Clinical study on Hanshibi granules combined with celecoxib in the treatment of ankylosing spondylitis

Wang Baohui; Fan Xiaochen; Lei Tao

doi:10.3760/j.issn.1673-4777.2024.09.021

Abstract：Objective To investigate the effect of Hanshibi granules combined with celecoxib in the treatment of ankylosing spondylitis.Methods A total of 128 patients with ankylosing spondylitis admitted to Honghui Hospital Affiliated to Xi'an Jiaotong University from January 2020 to August 2023 were selected.According to the random number table method,the patients were divided into control group and observation group,with 64 cases in each group.The control group was treated with celecoxib capsule,and the observation group was treated with Hanshibi granules on the basis of the control group.Both groups were treated for 6 weeks.The therapeutic effect,visual analogue scale(VAS)score,Bath ankylosing spondylitis functional index(BASFI)score,serum inflammatory indexes and adverse reactions were compared between the two groups.Results In the control group,54 cases were improved and 10 cases were ineffective.In the observation group,61 cases were improved and 3 cases were ineffective.The total effective rate of the observation group was higher than that of the control group[95.3％(61/64)vs 84.4％(54/64)](x2=4.195,P=0.041).After treatment,the VAS and BASFI scores of the two groups were lower than those before treatment,and those of the observation group were lower than those of the control group(all P＜0.05).After treatment,the levels of C-reactive protein,interleukin-17 and tumor necrosis factor-α in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(all P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(x2=0.175,P=0.676).Conclusion The combination of celecoxib and Hanshibi granules in the treatment of ankylosing spondylitis can achieve satisfactory results.It can rapidly improve the clinical symptoms such as low back pain,morning stiffness,aralgia and so on,reduce VAS,BASFI scores and inflammatory response in the body,with a low incidence of adverse reactions and mild symptoms.